Skip to Main Content Skip to Site Map Skip to Accessibility Statement
Home Formulary 6.0 Endocrine 6.4 Sex hormones 6.4.1 Hormone replacement therapy (HRT) for menopausal symptoms 6.4.1b Women who have had a total hysterectomy or who have a suitable LNG IUS in situ < 5 years

6.4.1b Women who have had a total hysterectomy or who have a suitable LNG IUS in situ < 5 years

HRT shortages – if products are unavailable see SPS website for current availability and alternative products

Unopposed oestrogens (oral)

ChoiceDrug

1st choices

Elleste-Solo® 1mg, 2mg (estradiol) tablets
Or
Zumenon® 1mg, 2mg (estradiol) tablets

Unopposed oestrogens (transdermal)

ChoiceDrug
1st choiceEvorel® patches 50micrograms, 25micrograms, 75micrograms, 100micrograms/24 hours (estradiol)

Unopposed oestrogens (gel)

ChoiceDrug
1st choicesOestrogel® pump-pack 0.06% gel
Or
Sandrena® gel sachets 500micrograms, 1mg

Unopposed oestrogens (spray)

ChoiceDrug
1st choiceLenzetto® 1.53mg/dose transdermal spray

Prescribing Notes

  • HRT preparations should be brand prescribed to aid product identification.
  • It is recommended that the lowest dose of HRT based on relieving menopausal symptoms should be prescribed.
  • For women with an early menopause (<45 years), consider the higher dose of oestrogen for bone protection.
  • See 7.3.2.3 for levonorgestrel intrauterine system (LNG IUS) options.  Note, Mirena is licensed for use for endometrial protection as part of HRT for 4 years, but the FSRH supports its use for 5 years. Although Mirena is the only LNG-IUS licensed for endometrial protection, FRSH endorse the use of any 20micrograms/24 hours LNG-IUS for up to 5 years as endometrial protection as part of HRT. See FSRH.

Preparations for vaginal atrophy

See section 7.2.1

Also in this Section